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Objectives: To estimate the clinical and economic trade-offs involved in using the 
molecular assay EPICUP to aid in identifying the primary site in Cancer of Unknown 
Primary (CUP). MethOds: A decision-analytic model was developed to estimate 
the lifetime clinical and economic outcomes of incorporating the EPICUP assay 
compared with other molecular assays (CancerTYPE ID, Cancer Origin Test and 
ResponseDX: Tissue of Origin Test). The analysis was limited to 6 primary cancer 
sites (breast, colon, pancreas, lung, liver and prostate) for adenocarcinoma histo-
logical subtype. Results are presented as incremental cost-effectiveness ratio (ICER, 
cost per quality-adjusted life-years [QALY] gained) from the USA Health Payers 
perspective. Model inputs were based on a case-control study of EPICUP, published 
literature, Surveillance Epidemiology and End Results database and a clinical expert 
panel. Results: Based on a price of USD3,500 for EPICUP and for a willingness to 
pay USD100,000, EPICUP is cost-effective (vs. CancerTYPE ID, Cancer Origin Test and 
ResponseDX: Tissue of Origin Test) in all tumors analyzed, ranging between 80% and 
100% of the simulations. EPICUP increased the proportion of patients treated cor-
rectly, decreased the proportion of patients treated with an empiric approach, and 
increased the quality-adjusted overall survival. For a willingness to pay USD50,000 
EPICUP is cost-effective in breast, colon, pancreas, lung (NSCLC) and prostate can-
cer, again ranging between 80% and 100% of the simulations. These findings were 
robust across deterministic and probabilistic sensitivity analyses. cOnclusiOns: 
EPICUP assay for diagnosing the primary tumor in CUP patients is a cost-effective 
approach in breast, colon, pancreas, lung (NSCLC), hepatocellular and prostate can-
cer in comparison with other alternatives available, while improving patient care.
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Objectives: To assess the health effectiveness, cost and cost-effectiveness of dif-
ferent oral anticoagulation therapies in China including warfarin plus International 
Normalized Ratio (INR) test in hospital labs (Lab test), warfarin plus patient 
self-test (PST) with point of care device, and novel anticoagulant (Dabigatran) 
alone. MethOds: A Markov model containing four states (no complication, haem-
orrhagic event, thrombotic event and death) was developed to account for long term 
cost and outcomes of warfarin/novel anticoagulant users including atrial fibrilla-
tion patients and deep venous thrombosis patients. Only direct medical cost was 
taken into consideration, covering expenses of drugs, OAT monitoring and compli-
cation management. Both clinical and economic parameters were mainly derived 
from literatures. Results: The hospital lab test pattern achieved 7.46 LYs and 4.43 
QALYs with a total cost of CNY 28,277 (USD 4,561), while the PST pattern obtained 
a prolonged 8.79 LYs and 5.30 QALYs with the larger amount of cost, CNY 45,992 
(USD 7,418). Comparably, the novel anticoagulant pattern acquired 8.08 LYs and 
4.87 QALYs and the cost was significant higher reaching CNY 99,545 (USD 16,056), 
dominated by PST pattern due to shortened QALYs while increased cost. The ICER of 
PST versus hospital lab test came to CNY 20,363 (USD 3,284) per QALY gained, lower 
than China GDP per capita in 2014 (CNY 42,900). Sensitivity analysis demonstrated 
the results were not sensitive to main indicators, including utility in different health 
status, complication probability and disease management cost. cOnclusiOns: 
Compared with OAT management in hospital laboratory, PST can generate more 
QALYs by reducing the risk of major thrombotic and bleeding events with acceptable 
incremental cost, which turns to be the most cost effective among the 3 patterns 
and demonstrates promising future in OAT management.
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Objectives: To estimate the clinical and economic trade-offs involved in using the 
molecular assay EPICUP to aid in identifying the primary site in Cancer of Unknown 
Primary (CUP). MethOds: A decision-analytic model was developed to estimate the 
lifetime clinical and economic outcomes of incorporating the EPICUP assay com-
pared with standard care and other molecular assays (CancerTYPE ID, Cancer Origin 
Test and ResponseDX: Tissue of Origin Test). The analysis was limited to 6 primary 
cancer sites (breast, colon, pancreas, lung, liver and prostate) for adenocarcinoma 
histological subtype. Results are presented as incremental cost-effectiveness ratio 
(ICER, cost per quality-adjusted life-years [QALY] gained) from the Spanish National 
Health System (NHS) perspective. Model inputs were based on a case-control study 
of EPICUP, published literature, Surveillance Epidemiology and End Results database 
and, a clinical expert panel. Results: Based on a price of € 3,000 for EPICUP, the 
cost per QALY gained with EPICUP was € 3,878 versus CancerTYPE ID and € 3,406 
versus Cancer Origin Test in breast cancer; € 5,889 and € 7,186, respectively, in colon 
cancer; € 4,294 and € 23,937, respectively, in pancreatic cancer; € 7,188 and € 16,840, 
respectively, in NSCLC; € 784 and € 20,444, respectively, in hepatocellular cancer; and 
Objectives: To develop an economic evaluation to compare individually and vial-
packaged strips for glucose monitoring. MethOds: A simple decision tree model was 
developed using Excel to compare the costs of using individual vs. vial-packaged strips 
in a hospital setting. The decision tree described costs and consequences associated 
with two main parameters: risk of nosocomial infection due to the contamination 
of strips and risk of hypoglycemia/hyperglycemia due to an error in the determina-
tion of glycemia induced by the storage conditions of the strips. For each alternative 
(IP and VP), a simulated cohort of 1000 patients went through the tree accounting for 
costs and effects, and the results were expressed as hypoglycemic events, nosoco-
mial infection events, use/waste of strips and ICER. Sources of parameters is wide 
and uncertainty is high. Due to the lack of information about certain parameters, a 
group of assumptions were made .The risk of measurement error using contaminated 
strips was modelled to account for hypoglycaemic events. Uncertainty was tested 
using one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). 
Cost-effectiveness acceptability curve with a threshold of 25.000€ /QALY was drawn. 
Probabilistic results were depicted using a CE plane. Results: Individual packaged 
strips save money (1,162 € per patient) and get more QALYs (0.023 per patient), which 
confers a dominant position to individual packaged strips with 11% less nosocomial 
events, 10 times less hypoglycemic events (53 vs 655) and 6% reduction in the use of 
strips. PSA shows results in the same direction with a 64% probability of being cost-
effective under a threshold of 25,000 € (from 82% at 0 € and keeping the difference 
over 25,000 € ). cOnclusiOns: Under the assumption of wrong measurements due 
to bad storage conditions, the use of individual packaged strips is a dominant option 
over vial-packaged strips, reducing costs by a 25%.
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Objectives: To compare the effectiveness and costs in the Colombian setting (and 
estimate the incremental cost-effectiveness ratio ICER) of the most commonly 
used schemes for screening and diagnosis of type 2 diabetes mellitus in local adult 
population. MethOds: We evaluated four possible schemes, all involved fasting 
blood sugar test, two with and two without previous screening with the FINDRISC 
scale; and, in a second step, using either the oral glucose tolerance, or glycosylated 
hemoglobin tests, for confirmation of diagnosis. We designed a decision tree model 
with correctly identified cases as the main effectiveness outcome (estimated for 
Colombia from a global systematic literature review). Direct medical costs were 
estimated from the third party payer perspective (healthcare system), in Colombian 
pesos for 2014 (1 € = COP 2,660). Base cases, analyzed and validated by multidis-
ciplinary expert panel, were used for resource estimation. Official cost databases 
and tariff manuals were then applied to estimate costs. No discount rates were 
applied. Univariate and probabilistic sensitivity analyses were performed. Results: 
The schemes that used glycosylated hemoglobin test for confirmation were domi-
nated. For a cohort of 1,000 people, the strategy of FINDRISC plus fasting blood 
sugar test plus oral glucose tolerance reported 969 correctly identified cases with 
a total cost of € 7,306; while fasting blood sugar test plus oral glucose tolerance 
detected 983 at a cost of € 10,880. Comparing these two schemes, the incremental 
cost effectiveness ratio is € 255. Sensitivity analyses did not significantly affect the 
results. cOnclusiOns: This study suggests that the scheme FINDRISC plus fast-
ing blood sugar test plus oral glucose tolerance is the most appropriate strategy for 
screening and diagnosis of type 2 diabetes in Colombia.
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Objectives: Antibiotics are often recommended as treatment for patients with 
COPD exacerbations. However, in many cases COPD exacerbations are not caused by 
a bacterial inflammation and antibiotics are prescribed unnecessary. Procalcitonin 
(PCT) is a biomarker with good specificity to distinguish bacterial from non-bacte-
rial inflammations. It can prevent unnecessary antibiotic prescriptions and reduce 
duration of antibiotic therapy. The goal of this study is to compare the health and 
economic consequences of using a PCT-algorithm compared to current practice in 
hospitalized patients with COPD exacerbations. MethOds: A decision tree was 
developed, comparing the expected costs and effects of the PCT-algorithm to cur-
rent practice in the UK, Germany and the Netherlands. The time horizon of the 
model captures the length of hospital stay and a societal perspective was adopted. 
Model input data are based on a systematic literature research, country specific cost 
data sources and expert opinions. The primary health outcome was the duration 
of antibiotic therapy; the incremental cost-effectiveness ratio was defined as the 
incremental costs per antibiotic day avoided. Results: Using a PCT-algorithm is 
expected to be cost-saving and more effective compared to current practice in all 
three countries. The incremental cost savings per antibiotic day avoided range from 
€ 125 in Germany and € 90 in the Netherlands, to € 52 in the UK. Probabilistic sensi-
tivity analyses showed that the PCT-algorithm tends to dominate current practice, 
though decision uncertainty remains (Germany: 58%, UK: 57%, the Netherlands: 
58%). Duration of hospital stay at baseline is the driver of the expected cost-savings 
in all three countries while reduction in antibiotic days drives the incremental effec-
tiveness of the PCT-algorithm. cOnclusiOns: A PCT-algorithm is a cost-effective 
way to guide the initiation and duration of antibiotic therapy when compared to 
current practice in COPD patients hospitalized with an exacerbation.
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the percentage of CCTA patients by 19.1%, shorter the diagnosis time by 8.45 
hours, decrease the length of stay by 0.64 days, increasing direct discharge rate 
by 9% and lower median cost of care per patient by 600 yuan while comparing 
to regular CT. cOnclusiOns: Results of this study indicate more serviceable 
patient population, faster hospital discharge, shorter diagnosis time, length of 
stay and lower hospitalization costs with the use of revolution CT. The revolution 
CT is more cost effective.
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Objectives: Approximately 18-20% of non-valvular atrial fibrillation (NVAF) 
patients are unable or unwilling to tolerate oral anticoagulant therapy (OAT), leav-
ing them at risk of stroke. Left atrial appendage closure (LAAC) device offers an 
alternative stroke risk reduction strategy that enables the majority of patients to dis-
continue long-term systematic OAT. Acknowledging both potential improvements 
in health outcomes and additional upfront implantation costs of a LAAC device, 
this study considers the lifetime costs and benefits of LAAC compared to aspirin 
plus clopidogrel (A+C) in high-risk NVAF patients ineligible or unwilling to take 
OAT from the Italian and Spanish public healthcare payer perspectives. MethOds: 
A Markov model was constructed to assess the cost-effectiveness of LAAC com-
pared to A+C. Due to the lack of direct clinical trial data an indirect comparison 
was undertaken; having warfarin as the common comparator, PROTECT-AF (mean 
follow-up: 3.8 years) and ACTIVE-W (1.3 years) trials were used to indirectly com-
pare LAAC against A+C. Clinical results were combined with cost and utility data 
to assess the relative cost-effectiveness of the device. Furthermore, to reflect the 
real-world patient population, patients were stratified according to the severity of 
stroke and bleeding using CHA2DS2-VASc and HAS-BLED scores. Results: The 
base-case results demonstrate the LAAC as the cost-effective strategy compared 
to A+C in both countries with ICERs of € 5,116 per life-year gained (LYG) and € 3,942 
per quality-adjusted life year (QALY) gained for Italy, and € 10,298 per LYG and € 7,683 
per QALY gained for Spain. The ICERs per QALY gained are significantly below the 
willingness-to-pay thresholds generally accepted by each country: € 25,000 in Italy 
and € 30,000 in Spain. Results also demonstrate that the clinical benefit of LAAC 
becomes greater when risk of stroke and bleeding increases. cOnclusiOns: LAAC 
device should be prioritised in patients who require an alternative to OAT and at 
relatively higher risk of stroke or bleeding.
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Objectives: This study was carried out to assess, from the viewpoint of cost-effec-
tiveness, the optimum number of blood cultures for adults patients with infection 
in China. MethOds: A decision tree was conducted for a cohort of Chinese adults 
aged 18 and above with infection and simulated the effects of only one-time, two-
time and three-time blood cultures. The detection rate and survival rate of compli-
cations were main outcomes and infectious endocarditis, meningitis, septic shock 
and kidney failure were considered as complications of infection in the model. The 
cost of blood culture, antibiotics and complications, the detection rate, incidence 
and survival rate of complications were collected from literature reviews. Sensitivity 
analyses were conducted to evaluate assumptions of the model and to identify 
which model inputs had most impact on the results. Results: The detection rate 
and the survival rate of complications were calculated as 65 and 97.9% for one-time 
blood culture, 80 and 98.0% for two-time blood cultures and 96 and 98.2% for three 
blood cultures, respectively. When using detection rate as outcome and willing to 
pay is more than RMB500 yuan, two-time blood cultures were cost-effective. The cost 
of blood culture and the detection rate will affect the results. When using survival 
rate of complications as outcome, two-time blood cultures was cost-saving and 
better than one-time blood culture. cOnclusiOns: This analysis suggests that 
a 2-time blood culture collection method is recommended for blood culture for 
patients aged 18 and over with infection from the aspects of cost-effectiveness and 
diagnostic accuracy in China.
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Objectives: The development of antidrug antibody (ADAb) causes the failure of ini-
tial tumor necrosis factor-alpha blocker (TNF-α blocker) in rheumatoid arthritis (RA) 
patients. Patients who develop ADAb against 1st TNF-blocker have a high likelihood 
of failing to 2nd TNF-blocker. ADAb-screening is commonly used as a supportive tool 
for switching to 2ndTNF-α blocker or non-TNF biologics in Europe but not standard 
of care in the United States. Moreover, no evidence of value of ADAb-screening 
in RA patients exists. This study estimated incremental effectiveness and cost of 
€ 1,639 and € 2,116, respectively, in prostate cancer. EPICUP was dominant versus 
ResponseDX in all adenocarcinomas. Regarding the comparison with diagnostic 
standard of care, the ICER was € 15,972 for breast cancer; € 25,932 for colon can-
cer; € 36,125 per QALY for pancreatic cancer; € 41,571 per QALY for NSCLC cancer; 
€ 28,881 per QALY for hepatocellular cancer; and € 6,771 per QALY for prostate cancer. 
These results were robust across deterministic and probabilistic sensitivity analy-
ses. cOnclusiOns: From the Spanish NHS perspective, EPICUP is a cost-effective or 
dominant approach in comparison with other alternatives, including standardizing 
diagnostic methods (in this case when considering WTP threshold € 50,000), in all 
carcinoma analyzed, while improving patient care.
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Objectives: To evaluate the cost-effectiveness of a new covered stent (WILLIS) 
vs. endovascular coil occlusion for the treatment of intracranial aneurysms in 
china. MethOds: A decision tree model was constructed and the treatment 
impact was projected up to 6 months. 88 endovascular coil occlusion treated 
initial intracranial aneurysms patients and 34 recurrence intracranial aneurysms 
patient (with aneurysm diameter > 7 mm) charts were reviewed and direct medical 
cost data were collected from hospital information system in multi-hospitals in 
12 cities in China. Direct medical cost data, including drug cost, medical device 
cost, daily bed expenses, nursing fee, and examination cost were abstracted from 
the charts. The aneurysm recurrence rates by WILLIS and Coil treatments were 
obtained through literature review. The mortality rate of intracranial aneurysms 
recurrence, and side effects rates of treatments were collected through a direct 
expert survey. The main summary measure in this evaluation was incremental 
cost per death avoided. One way sensitivity analysis was performed to deter-
mine the robustness of the results. Results: The total direct medical cost was 
141,582.95 RMB and 177,407.35 RMB for Willis and coil occlusion treatments respec-
tively; the recurrence rate of intracranial aneurysms was 0% and28.9% for Willis 
and coil occlusion treatments in Chinese patients respectively; Relapse mortal-
ity of intracranial aneurysms is 0.2% in Chinese patients. The result suggests 
a dominant effect of Willis treatment over coil occlusion with an incremental 
cost-effectiveness ratio (ICER) of -63055263.7RMB/avoided death. This indicates 
that Willis treatment has demonstrated better efficacy and lower overall costs. 
The one-way sensitivity analysis didn’t change the conclusion, indicating the 
robustness of the results. cOnclusiOns: Compared with endovascular coil 
occlusion, a new covered stent (WILLIS) improves clinical outcomes and reduces 
overall medical costs for the treatment of Chinese intracranial aneurysms patients 
(Diameter > 7 MM).
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Objectives: The study –implemented after requirement of the National Cancer 
Institute (INC) - shows the results of a cost-effectiveness evaluation based on two 
alternative mechanisms: annual faecal immunochemical testing (FIT), and colonos-
copy every ten years in Argentina. MethOds: The study develops a Markov model 
in ten stages, based on information provided by the INC, prior literature review and 
on-line questionnaires to physicians enrolled in the four major scientific societies 
related to cancer. Cost information arrived from the National Superintendence of 
Social Health Insurances and a sample of managers in social and private insur-
ance schemes. Results: The estimated model suggests that FIT annually applied 
becomes the most cost-effective screening method for CRC, in comparison with 
both no intervention and just colonoscopy. The incremental cost-effectiveness for 
annual FIT screening is USD 220.- per quality- adjusted life years (QUALY) against 
no-intervention, and the cost-effectiveness ratio is low and acceptable considering 
the WHO criteria (per capita GDP), in comparison to the cost-effectiveness ratios of 
other cardio-vascular preventive interventions prices in Argentina. cOnclusiOns: 
Results of cost-effectiveness analyses are often strong associated to disbursements 
related to specific performance indicators, such as the challenges of implementing 
such initiatives under budget constraints and/or availability and quality of equip-
ments and human resources. These aspects were considered in the implementa-
tion of different scenarios in the sensitivity analysis, which includes adherence to 
treatments and capacity of accurate diagnoses, providing strength to the output 
reached in the research.
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Objectives: This study aimed to estimate the proportion of patients increas-
ing while using revolution CT and to evaluate the impact of it in diagnosis time, 
length of stay, rate of direct discharge and hospitalization costs, while comparing 
to regular CT MethOds: The data including rates, costs, time of diagnosis and 
length of stay, collected from literature reviewing and expert consultation, we use 
decision tree model to carry out a cost-effectiveness analysis by using treeage 
software Results: The study shows that with revolution CT, we can increase 
